港股異動 | 康希諾生物高開4.5% 旗下新冠疫苗CS-2034取得積極階段性數據
格隆匯1月6日丨康希諾生物高開4.5%,報72港元,總市值178億港元。康希諾生物5日公吿,集團開發的新型冠狀病毒mRNA疫苗CS-2034在一項評估序貫加強安全性和免疫原性的臨牀研究中,取得了積極的階段性數據。CS-2034是對現有變異株有保護效果的mRNA疫苗,臨牀前研究結果顯示,該款疫苗可以誘導出針對多種世界衞生組織認定的重要變異株的高滴度的中和抗體,與以原型株為基礎開發的新冠疫苗相比廣譜性更強,可以更有效地保護機體免受現有變異株的感染。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.